This map demonstrates the breadth of HIV prevention research and demonstration projects in South Africa by site and type (e.g. daily oral PrEP demo projects, ARV-based rings, long-acting injectable PrEP, preventative Vaccines, antibodies, hormonal contraceptives). This map was developed by Wits RHI with support from AVAC as part of the Coalition to Accelerate and Support Prevention Research. This graphic first appeared in AVAC Report 2017: Mixed messages and how to untangle them.
HIV Prevention Research and Demonstration Sites in South Africa
Global HIV Prevention R&D Investment by Technology Category, 2000-2017
In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion. The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.
HIV Prevention R&D Trial Participants by Region in 2017
Participation of volunteers and the engagement of communities in which trials take place is essential to conducting HIV prevention research. In 2017, there were nearly 600,000 participants in HIV prevention research trials globally, mostly originating from sub-Saharan Africa, Europe, North America and Asia. A majority of participants were enrolled in research investigating TasP and PrEP, and while there are trials aimed specifically at men who have sex with men (MSM), transgender individuals and people who inject drugs, most of the studies do not specify the need to include members of key populations.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.
Investment in HIV Prevention R&D by Top Philanthropic Funders in 2017
Global philanthropic funding increased by 4.1 percent from 2016 levels and amounted to US$164 million, or 14.6 percent of overall funding. The Bill and Melinda Gates Foundation (BMGF) remained the largest funder and increased its contribution by 6.6 percent, to US$150.2 million. Wellcome Trust investment fell for the fifth consecutive year to an annual US$2 million.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.
Investment in Women-Focused PrEP R&D, 2017
Out of the US$63 million invested in PrEP overall, US$16 million (or 25 percent) was for research explicitly focused on women. Most of this research was preclinical, with an emphasis on discreet products with long-acting formulations, e.g., PrEP implant studies and long-acting injectables. Almost 30 percent of the implementation studies focused on the uptake of and adherence to oral PrEP in high-risk women, and 15 percent focused on PrEP for pregnant and breastfeeding women.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.
HIV Prevention Research & Development Investments 2017: Investing to end the epidemic
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion (Figure 2). This is the fifth consecutive year of decreasing annual investment, with 2017 levels representing the lowest funding since 2005.
Click here for the full archive of past resource tracking reports.
Contraception and HIV Prevention: A clear picture of women’s needs
Women face many choices about HIV prevention and contraception. Funders and governments need to move to integrated programs that provide a variety of services in one place.
Anatomy of a Target
It’s been four years since AVAC advanced these criteria for effective targets in our 2014/15 Report, Prevention on the Line. Then, we identified targets that have advanced the field and ones that have fallen short. Today’s prevention crisis exists in part because the primary prevention targets set by UNAIDS didn’t meet these criteria. Targets for primary prevention are still essential, but they won’t get met without demand creation work, such as we describe in this section. It’s not too late to recalibrate resources and commitment.
Annual Number of VMMCs, 2008-2017
AVAC’s take on milestone events and impact on VMMC numbers.
Comparison of Traditional Socio-Behavioral Research and Human-Centered Design Approaches
The table below comes from an article by Betsy Tolley, which contrasts human-centered design (HCD) with “traditional socio-behavioral research” (SBR). It resists over-simplification like: “HCD looks for solutions, SBR looks for theories”, while also giving a sense of the differences between formal, protocol-driven SBR and a commerce– and private sector-derived methodology, now proving its worth in public health.